Table 1.

Response of p53 M135 SH-EP transfectants to cytotoxic drugs in 72-h cytotoxicity assays

DrugCell lineID50Fold resistance *P
KATSHEP/CMV6.731 ± 1.115 μg/mL
SHEP/M13515.943 ± 1.834 μg/mL2.370.023
Log (drug) ± SE M §
DoxorubicinSHEP/CMV−7.690 ± 0.0502.042 × 10−8
SHEP/M135−7.119 ± 0.0567.603 × 10−83.72<0.001
VincristineSHEP/CMV−9.163 ± 0.0286.87 × 10−10
SHEP/M135−8.550 ± 0.0352.82 × 10−94.10<0.001
VM26SHEP/CMV−6.987 ± 0.0831.03 × 10−7
SHEP/M135−5.928 ± 0.1071.18 × 10−611.46<0.001
CisplatinSHEP/CMV−5.851 ± 0.0301.41 × 10−6
SHEP/M135−5.517 ± 0.0373.04 × 10−62.16<0.001
MethotrexateSHEP/CMV−7.834 ± 0.0921.47 × 10−8
SHEP/M135−7.564 ± 0.1012.73 × 10−81.86NS
TaxolSHEP/CMV−8.261 ± 0.0615.48 × 10−9
SHEP/M135−8.166 ± 0.0466.82 × 10−91.24NS
  • Abbreviation: NS, not significant.

  • * The fold resistance was determined by dividing the ID50 of the p53 M135–transfected SH-EP cells by that of the vector control SH-EP/CMV cells.

  • For a given drug, P values were determined by comparing the ID50 value for the p53 M135–transfected SH-EP cells with the ID50 value of the control SH-EP/CMV cells assayed in the same series of experiments.

  • Calculated from at least three replicate assays.

  • § Molar concentration.